PET-fluorodeoxyglucose of cranial and spinal neuromas.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 1432151.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Five patients with eighth nerve, one with ninth nerve and one with cervical neuromas were studied with PET and [18F] fluorodeoxyglucose (FDG). Four of the patients had had surgery prior to the PET study, and six patients had subsequent surgery. All tumors were well-visualized on the PET images. Only one patient with bilateral acoustic neuroma exhibited tumor recurrence or growth after the PET study; these two lesions showed the highest FDG uptakes in the PET studies (tumor-to-cerebellum ratio of 0.93-0.98). All other tumors were relatively hypometabolic (tumor-cerebellum ratios of 0.43-0.65) and showed no tumor growth or recurrence during follow-up periods ranging from 5 to 8 yr. These results suggest that PET-FDG may be of value in the evaluation of cranial and spinal schwannomas.
Medical subject headings
- Cranial Nerve Neoplasms
- Deoxyglucose
- Neuroma
- Neuroma, Acoustic
- Peripheral Nervous System Neoplasms
- Spinal Nerves
- Tomography, Emission-Computed